newstock.ai
← Back

VRTXVertex Pharmaceuticals

$515.44+0.17%Real quote · delayedBiopharmaPharma & biotech · 16 peers →

🏛️ Company factsSEC filings + FINRA official data

Annual revenue $12.0B · latest quarter up 12.5% YoY · profitable (FY net income $4.0B) · short activity within its normal range.

FY revenue

$12.0B

2025-12

Latest Q YoY

+12.5%

FY net income

$4.0B

Diluted EPS

$15.46

Short volume

63%

20d avg 62.2% · normal

🐋 5%+ ownership filings (last 180d)

The parties below hold over 5% of this company and disclosed it to the SEC (mandatory in US markets). "Activist" filers state an intent to influence the company; "Passive" are pure investment positions.

🎯 Market expectations

Expectation reliability High · 74/100

Nasdaq analyst consensus · the pre-news baseline

Next quarter (Sep 2026) consensus$4.40Estimate range $4.34 ~ $4.46 · 6 analystsRevisions (4w):1
History: actual vs consensusavg +4.9%
  • Jun 2026$4.20 vs $4.15+1.2%
  • Mar 2026$3.95 vs $3.69+7.05%
  • Dec 2025$4.65 vs $4.40+5.68%
  • Sep 2025$4.22 vs $4.00+5.5%

The takeaway

This company habitually beats by +4.9% — the next report has to clear that bar to count as good news.

Analyst estimates, not our forecast · not investment advice

What's moving this stock lately

No recent news affecting this stock

🕰️ Price × news · engine report card

Drag to pan, scroll to zoom · real daily bars and volume

The 8 engine calls on this chart (hit / miss / pending) are Pro — price and volume only for nowvolume

📜 Call history (newest first

🔒 Pro only

8 engine calls on this stock — each with direction, magnitude and its verified outcome · sign up to view

Sign up · free 7-day trial →
🔒 Pro only

Impact chains · crowding · conviction engine · insider signals — free 7-day trial on signup.

Sign up · free 7-day trial →